BURLINGTON, Mass., April 25, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced the appointment of Karin Hehenberger, M.D., Ph.D., formerly Senior Vice President of Scientific Affairs, to Executive Vice President and Chief Medical Officer. In this new capacity, Dr. Hehenberger will be responsible for providing strategic scientific input and oversight of the company's clinical development programs and medical affairs, which expands upon her previous role of broadening the scope of proof of concept trials in autoimmune diseases for the company's lead compound TSO (Trichuris suis ova or CNDO-201).
Dr. Bobby W. Sandage, Jr., Coronado's President and CEO said, "Karin's extensive clinical and industry expertise makes her an outstanding choice for Chief Medical Officer. Since joining Coronado, she has been instrumental in increasing awareness of TSO within the medical community. We look forward to Karin's leadership in our continued development of TSO for the treatment of autoimmune diseases and CNDO-109 for the treatment of cancer."
Prior to joining Coronado Biosciences, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial, and commercial partners in the diabetes community. Dr. Hehenberger joined the JDRF from Johnson & Johnson, where she served as Vice President of Metabolic Strategy and Business Development. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School and then moved into the business aspect of medicine, as a strategic management consultant at McKinsey & Co. Dr. Hehenberger also has experience in public and private equity, having been a partner in Scandinavian Life Science Venture, a Scandinavian-based venture capital company, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, and on the senior management team of Eyetech Pharmaceuticals.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Relations Lucy Lu, MD, Executive Vice President & Chief Financial Officer Coronado Biosciences, Inc. 781-238-6619; Marcy Nanus, Vice President The Trout Group, LLC. 646-378-2927; Media Relations Dennis S. Dobson Jr., CEO Dobson Media Group 203-258-0159;